ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".
- 1 September 1981
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 318 (8246) , 543-547
- https://doi.org/10.1016/s0140-6736(81)90937-5
Abstract
No abstract availableFunding Information
- National Institutes of Health (RR-533, HL 18318)
- U.S. Public Health Service (RR-533, HL 18318)
This publication has 27 references indexed in Scilit:
- A new class of angiotensin-converting enzyme inhibitorsNature, 1980
- CAPTOPRIL AND AGRANULOCYTOSISThe Lancet, 1980
- Adverse Effects of D-Penicillamine in Rheumatoid ArthritisAnnals of Internal Medicine, 1980
- NEPHROTIC SYNDROME IN PATIENT ONThe Lancet, 1979
- Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting EnzymeNew England Journal of Medicine, 1979
- IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRILThe Lancet, 1979
- Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.Hypertension, 1979
- Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive PatientsAnnals of Internal Medicine, 1979
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978